Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Thursday, June 6, 2024

Medtronic unveils next-generation Artisse intrasaccular device alongside new data at LINNC Paris 2024

 Ask your competent? doctor and hospital about this. If they know nothing; RUN AWAY!

Medtronic unveils next-generation Artisse intrasaccular device alongside new data at LINNC Paris 2024

Medtronic has today announced the European launch of Artisse—a new intrasaccular device designed to treat intracranial aneurysms by conforming to the shape of the aneurysm. The launch coincides with interim data that examine the safety, efficacy and performance of the device being presented for the first time at LINNC Paris 2024 (3–5 June, Paris, France).

Artisse was designed to address the needs of complex wide-neck bifurcation aneurysms that have traditionally been managed by stent-assisted coiling, coil adjunctive neck-bridging devices and other intrasaccular basket devices. The former two methods require multiple steps and multiple devices, with stent-assisted coiling requiring dual antiplatelet therapy, which can present challenges in ruptured aneurysms.

Medtronic claims that Artisse offers a simple, one-step technique in treating these complex and simpler aneurysms alike.

Artisse is highly conformable, engineered from dual layers of high-density platinum core and nitinol drawn filled tubing (DFT) wires in a flared design. This sophisticated construction allows it to flex to conform to the unique contours of most aneurysms while exerting the optimum outward radial force needed to fill the space securely, the company also states in a recent press release.

“Artisse behaves differently to other intrasaccular devices because I can control the optimal positioning of the device in the aneurysm,” said Riitta Rautio (Turku University Hospital, Turku, Finland). “Due to its conformability and softness, I can reach the optimal position of Artisse in the aneurysm with partial re-sheathing of the device and slight movement of the microcatheter.”

The device’s flexibility, smooth distal tip and gentle deployment make Artisse atraumatic—reducing risk to, and stress on, the aneurysm walls.

Early-experience analysis presented at LINNC Paris 2024, from a study involving 35 patients enrolled into the multicentre, core lab-adjudicated European INSPIRE-A registry, shows that 80% of patients treated with Artisse achieved complete occlusion by a six-month angiographic assessment, indicating successful aneurysm occlusion with no residual filling.

“Artisse is a promising device that appears to be a step in the right direction for intrasaccular technology,” said Tufail Patankar (Leeds General Infirmary, Leeds, UK). “Its softness and conformability allows you to manipulate the device within the aneurysm. Complex wide-neck angled aneurysms that were previously difficult to treat with other intrasaccular devices now seem to be treatable with Artisse.”

According to Medtronic, Artisse is simple to use and faster when compared with coils, or balloon- or stent-assisted coiling. In deployment, the device opens gradually and smoothly with a ‘flowering mechanism’, with no kick-back, so that it feels like pushing a coil. The device also features a handheld electrolytic detachment system that provides immediate confirmation, instant audio and visual feedback upon detachment, and complete radiopacity.

Medtronic offers expert clinical support, including access to simulation software, further supporting sizing selection with Artisse, the recent release notes.

“At this time, I experience very satisfying results for both unruptured and ruptured aneurysms treated with the Artisse device,” said Cyril Dargazanli (University Hospital of Montpellier, Montpellier, France).

“Combined with simulation and the radial approach, Artisse is redefining the standard of care of unruptured aneurysms, offering each patient a safe and customised solution, reinforcing the perspective of aneurysm screening in populations at risk to finally achieve the ultimate goal of our community: reducing subarachnoid haemorrhage worldwide,” added Vincent Costalat (University Hospital of Montpellier, Montpellier, France).

No comments:

Post a Comment